High-performance liquid chromatographic determination of fluconazole in plasma and its application to a bioequivalence study by Sousa, Carlos E.M. et al.
1432 ISSN 0326-2383
KEY WORDS: Bioequivalence, Fluconazole, High performance liquid chromatography (HPLC), Validation. 
* Author to whom correspondence should be addressed. E-mail: eduardo.miranda@nudfac.com.br or davi.santana@nudfac.com.br
Latin American Journal of Pharmacy
(formerly Acta Farmacéutica Bonaerense)
Lat. Am. J. Pharm. 30 (7): 1432-6 (2011)
Short communication
Received: February 9, 2011
Revised version: April 5, 2011
Accepted: April 12, 2001
High-Performance Liquid Chromatographic Determination of
Fluconazole in Plasma and its Application to a Bioequivalence Study
Carlos E.M. de SOUSA, Danilo C.G BEDOR, L.C.A. SAMPAIO FILHO, T.M. SILVA,
F.N. BONIFÁCIO, Miracy M. ALBUQUERQUE & Davi P. de SANTANA*
Núcleo de Desenvolvimento Farmacêutico e Cosmético – NUDFAC- ,
Rua Professor Arthur de Sá s/n, Cidade Universitária, CEP 50740-520, Recife, Pernambuco, Brasil.
SUMMARY. A sensitive and accurate HPLC-UV method for the quantification of fluconazole (FNZ) in hu-
man plasma has been developed. The sample was prepared by liquid–liquid extraction (LLE) of FNZ from
plasma using ethyl acetate. Nevirapine (NVP) was used as internal standard. The chromatographic reten-
tion times of FNZ and NVP were 3.4 and 5.7 min, respectively. The lower limit of quantitation (LLOQ)
was 0.5 μg/mL, and no interferences were detected in the chromatograms. The HPLC-UV method was val-
idated by evaluating its intra-day and inter-day precisions and accuracies in a linear concentration range
between 0.5 and 8.0 μg/mL. The method was developed, validated and successfully applied to bioequiva-
lence studies involving the oral administration of a single 150 mg FNZ capsules in healthy Brazilian male
volunteers.
